의료 시뮬레이션 시장 : 제공별(해부 모델[환자용(고충실도), 외과용(복강경, 정형외과, 부인과), 트레이너, 초음파], 소프트웨어), 기술별(3D 프린팅, 가상 환자, 시술 리허설), 최종사용자별 - 세계 예측(-2030년)

The global medical simulation market is projected to reach USD 7.23 billion by 2030 from USD 3.50 billion in 2025, at a CAGR of 15.6%. The medical simulation market is growing due to increasing demand for advanced clinical training and investments in supporting infrastructure.

For example, the University of Texas at Arlington announced its Mobile Simulation Lab, launched in March 2025, aimed at delivering high-tech medical education in underserved parts of Texas, highlighting how simulation technologies are increasing access to hands-on education beyond traditional academic centers.

"Healthcare simulation anatomical models held the largest share of the medical simulation market."

Based on offering segment, healthcare simulation anatomical models held the largest share of the medical simulation market. This is because of their widespread use in foundational training and skills practice. These physical models help learners build core competencies in a risk-free environment before working with patients. For example, Kyoto Kagaku provides highly detailed anatomical phantoms for ultrasound and procedural skills training, and Limbs & Things offers realistic pelvic and neonatal models used in obstetrics and emergency care education, making anatomical models indispensable in medical and nursing curricula worldwide.

"Procedural rehearsal technology held the largest share of the medical simulation market in 2024."

The procedural rehearsal technology segment accounted for the largest share of the medical simulation market in 2024, driven by the need for hands-on practice of complex medical procedures. These technologies enable clinicians to simulate surgeries on highly realistic, often patient-specific models with improved accuracy and reduced intraoperative risk. Acceleration of adoption will be furthered by the rise of minimally invasive surgery, an increased focus on reducing complications, and greater investment in advanced imaging and 3D modeling. For example, various platforms from Surgical Science Sweden AB enable surgeons to rehearse laparoscopic and endoscopic procedures in virtual environments, effectively bridging the gap between theory and real-world execution in training and preoperative planning.

"Asia Pacific is growing at the fastest rate during the forecast period."

Asia Pacific is the fastest-growing region in the medical simulation market, driven by the rapid expansion of healthcare infrastructure, the growing need for skilled clinical resources, and the increasing adoption of state-of-the-art training solutions. For instance, in December 2025, the Indian government launched the second National Simulation Centre for nursing education in Bagalkot, equipped with high-fidelity simulators to help students improve their clinical skills, thereby indicating the general public's support for this sector in this region.

In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.

The breakdown of primary participants is as mentioned below:

• By Company Type - Tier 1: 55%, Tier 2: 30%, and Tier 3: 15%
• By Designation - C-level Executives: 50%, Directors: 35%, and Others: 15%
• By Region - North America: 48%, Europe: 32%, Asia Pacific: 15%, Middle East & Africa: 3%, and Latin America: 2%

Note: Other designations include sales, marketing, and product managers.

Tiers are defined based on a company's total revenue as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

Key Players in the Medical Simulation Market

The key players functioning in the medical simulation market include CAE Inc. (Canada), Laerdal Medical (Norway), Gaumard Scientific Co. (US), Kyoto Kagaku (Japan), Limbs & Things (UK), Mentice AB (Sweden), Simulab Corporation (US), Simulaids (US), 3B Scientific (Germany), and Operative Experience Inc. (UK), among others.

Research Coverage:

The report analyzes the medical simulation market. It aims to estimate the market size and future growth potential of various market segments based on offering, technology, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will help established firms and new entrants/smaller firms gauge the market's pulse, which, in turn, would help them garner a larger market share. Firms purchasing the report could use one or more of the strategies listed below to strengthen their market positions.

This report provides insights into:

• Analysis of key drivers (rising demand for realistic and risk-free training environments in medical education, rapid technological advancements in medical education, surging demand for minimally invasive treatment, increasing focus on patient safety, growing adoption of AI-driven VR platforms to improve clinical decision-making), restraints (limited availability of funds to establish simulation training centers, poorly designed medical simulators), opportunities (widening workforce gaps creating demand for simulation-based training solutions, growing awareness about simulation training in emerging economies), and challenges (high cost of simulators, operational challenges) influencing the growth of the medical simulation market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product & service launches in the medical simulation market.
• Market Development: Comprehensive information on the lucrative emerging markets, products & services, technologies, end users, and regions.
• Market Diversification: Exhaustive information about the product portfolios, untapped geographies, recent developments, and investments in the medical simulation market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the medical simulation market such as CAE Inc. (Canada), Laerdal Medical (Norway), Gaumard Scientific Co. (US), Kyoto Kagaku (Japan), Limbs & Things (UK), Mentice AB (Sweden), Simulab Corporation (US), and Simulaids (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 STUDY SCOPE
  • 1.2.2 INCLUSIONS & EXCLUSIONS
  • 1.2.3 YEARS CONSIDERED
• 1.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 ATTRACTIVE OPPORTUNITIES FOR MEDICAL SIMULATION MARKET
• 3.2 NORTH AMERICA: MEDICAL SIMULATION MARKET, BY END USER AND COUNTRY
• 3.3 MEDICAL SIMULATION MARKET, BY COUNTRY

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
• 4.3 MARKET DYNAMICS: IMPACT ANALYSIS
  • 4.3.1 DRIVERS
    • 4.3.1.1 Rising demand for realistic and risk-free training environments in medical education
    • 4.3.1.2 Rapid technological advancements in medical education
    • 4.3.1.3 Surging demand for minimally invasive treatments
    • 4.3.1.4 Increasing focus on patient safety
    • 4.3.1.5 Growing adoption of AI-driven VR platforms to improve clinical decision-making
  • 4.3.2 RESTRAINTS
    • 4.3.2.1 Limited availability of funds to establish simulation training centers
    • 4.3.2.2 Poorly designed medical simulators
  • 4.3.3 OPPORTUNITIES
    • 4.3.3.1 Widening workforce gaps creating demand for simulation-based training solutions
    • 4.3.3.2 Growing awareness about simulation training in emerging economies
  • 4.3.4 CHALLENGES
    • 4.3.4.1 High cost of simulators
    • 4.3.4.2 Operational challenges
• 4.4 UNMET NEEDS & WHITE SPACES
• 4.5 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.6 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 THREAT OF NEW ENTRANTS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 GDP TRENDS & FORECAST
  • 5.2.2 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE PRICING ANALYSIS OF MEDICAL SIMULATION PRODUCTS, BY KEY PLAYER, 2025
  • 5.5.2 INDICATIVE PRICING ANALYSIS OF MEDICAL SIMULATION PRODUCTS, BY REGION, 2025
• 5.6 KEY CONFERENCES & EVENTS, 2026-2027
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 INVESTMENT & FUNDING SCENARIO
• 5.9 CASE STUDY ANALYSIS
  • 5.9.1 CASE STUDY 1: ENHANCING CLINICAL READINESS: NORTHUMBRIA UNIVERSITY'S SCALABLE SIMULATION PROGRAM IN PARTNERSHIP WITH OMB
  • 5.9.2 CASE STUDY 2: OPTIMIZING PATIENT FLOW AND INFRASTRUCTURE: MEMORIAL HEALTH SYSTEM'S SIMULATION-DRIVEN EFFICIENCY GAINS WITH SIMUL8
• 5.10 IMPACT OF 2025 US TARIFFS ON MEDICAL SIMULATION MARKET
  • 5.10.1 INTRODUCTION
  • 5.10.2 KEY TARIFF RATES
  • 5.10.3 PRICE IMPACT ANALYSIS
  • 5.10.4 IMPACT ON COUNTRY/REGION
    • 5.10.4.1 US
    • 5.10.4.2 Europe
    • 5.10.4.3 Asia Pacific
  • 5.10.5 IMPACT ON END-USE INDUSTRIES
    • 5.10.5.1 Academic institutes
    • 5.10.5.2 Hospitals
    • 5.10.5.3 Military organizations

6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 COMPUTER-BASED SIMULATIONS
  • 6.1.2 HAPTIC FEEDBACK DEVICES
  • 6.1.3 ARTIFICIAL INTELLIGENCE & VIRTUAL REALITY
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 BIG DATA & INTEROPERABILITY PLATFORMS
  • 6.2.2 LEARNING MANAGEMENT SYSTEMS (LMS)
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 CLOUD COMPUTING
  • 6.3.2 ROBOTICS
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PATENT ANALYSIS
  • 6.5.1 PATENT PUBLICATION TRENDS FOR MEDICAL SIMULATION MARKET
  • 6.5.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
• 6.6 FUTURE APPLICATIONS
  • 6.6.1 AI-DRIVEN ADAPTIVE SIMULATION & PERFORMANCE ANALYTICS
  • 6.6.2 DIGITAL TWIN-ENABLED PATIENT-SPECIFIC SIMULATION
  • 6.6.3 IMMERSIVE XR-BASED COLLABORATIVE TRAINING ENVIRONMENTS
  • 6.6.4 REMOTE, CLOUD-BASED SIMULATION, AND SCALABILITY
  • 6.6.5 HAPTIC INNOVATION & HIGH-FIDELITY PHYSICAL-DIGITAL INTEGRATION
  • 6.6.6 SIMULATION FOR CLINICAL DECISION SUPPORT & RISK REDUCTION
• 6.7 IMPACT OF AI/GEN AI ON MEDICAL SIMULATION MARKET
  • 6.7.1 MARKET POTENTIAL OF AI/GEN AI
  • 6.7.2 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
    • 6.7.2.1 AI-driven surgical simulation and performance analytics at Surgical Science Sweden AB
  • 6.7.3 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
    • 6.7.3.1 AI-driven adaptive simulation and training platforms
    • 6.7.3.2 Virtual patients, digital twins, and simulation intelligence
    • 6.7.3.3 Remote simulation, collaboration, and skill validation
  • 6.7.4 USER READINESS & IMPACT ASSESSMENT
    • 6.7.4.1 User readiness
      • 6.7.4.1.1 User A: Academic institutes
      • 6.7.4.1.2 User B: Hospitals
      • 6.7.4.1.3 User C: Military organizations
    • 6.7.4.2 Impact assessment
      • 6.7.4.2.1 User A: Academic Institutes
      • 6.7.4.2.2 User B: Hospitals
      • 6.7.4.2.3 User C: Military organizations

7 REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS IN BUYING PROCESS & THEIR EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM END-USE INDUSTRIES
  • 8.4.1 UNMET NEEDS
  • 8.4.2 END-USER EXPECTATIONS
• 8.5 MARKET PROFITABILITY

9 MEDICAL SIMULATION MARKET, BY OFFERING

• 9.1 INTRODUCTION
• 9.2 HEALTHCARE SIMULATION ANATOMICAL MODELS
  • 9.2.1 PATIENT SIMULATORS
    • 9.2.1.1 Patient simulators market, by type
      • 9.2.1.1.1 High-fidelity patient simulators
        • 9.2.1.1.1.1 Growing adoption of high-fidelity patient simulators in educational training to drive growth
      • 9.2.1.1.2 Medium-fidelity patient simulators
        • 9.2.1.1.2.1 Cost benefits of medium-fidelity simulation to drive demand
      • 9.2.1.1.3 Low-fidelity patient simulators
        • 9.2.1.1.3.1 Budgetary constraints and ease of use to drive demand
    • 9.2.1.2 Patient simulators market, by application
      • 9.2.1.2.1 Laparoscopic surgical simulators
        • 9.2.1.2.1.1 Increasing prevalence of minimally invasive surgeries to drive growth
      • 9.2.1.2.2 Gynecology simulators
        • 9.2.1.2.2.1 Increasing incidence of fibroids and polyps in women to drive demand
      • 9.2.1.2.3 Cardiovascular simulators
        • 9.2.1.2.3.1 Increasing prevalence of diabetes to boost demand
      • 9.2.1.2.4 Orthopedic surgical simulators
        • 9.2.1.2.4.1 Enhancement in surgeon skills by orthopedic simulation training to drive demand
      • 9.2.1.2.5 Spine surgical simulators
        • 9.2.1.2.5.1 Mastering spine surgeries through advanced simulation techniques to boost demand
      • 9.2.1.2.6 Endovascular simulators
        • 9.2.1.2.6.1 Reduced mortality rates associated with endovascular simulators to boost demand
      • 9.2.1.2.7 Other patient simulators
  • 9.2.2 TASK TRAINERS
    • 9.2.2.1 Inability to imitate emotional attributes of patients to restrain growth
  • 9.2.3 INTERVENTIONAL/SURGICAL SIMULATORS
    • 9.2.3.1 Laparoscopic surgical simulators
      • 9.2.3.1.1 Increasing preference for minimally invasive surgeries to drive growth
    • 9.2.3.2 Gynecology surgical simulators
      • 9.2.3.2.1 Increasing incidence of fibroids and polyps in women to drive demand for gynecology simulators
    • 9.2.3.3 Cardiovascular surgical simulators
      • 9.2.3.3.1 Increasing prevalence of obesity and diabetes to boost demand
    • 9.2.3.4 Orthopedic surgical simulators
      • 9.2.3.4.1 Enhancement in surgeon skills by orthopedic simulation training to drive demand
    • 9.2.3.5 Spine surgical simulators
      • 9.2.3.5.1 Growing use of spine surgical simulators in training surgeons to boost demand
    • 9.2.3.6 Endovascular surgical simulators
      • 9.2.3.6.1 Ability to reduce mortality rates to drive demand for endovascular surgical simulators
    • 9.2.3.7 Other interventional/surgical simulators
  • 9.2.4 ULTRASOUND SIMULATORS
    • 9.2.4.1 Inferior quality images due to low dynamics and spatial resolution to restrain growth
  • 9.2.5 DENTAL SIMULATORS
    • 9.2.5.1 Expanding dental tourism industry to drive growth
  • 9.2.6 EYE SIMULATORS
    • 9.2.6.1 Increasing incidence of eye disorders to drive growth
• 9.3 WEB-BASED SIMULATION
  • 9.3.1 RISING TECHNOLOGICAL ADVANCEMENTS TO DRIVE ADOPTION OF WEB-BASED SIMULATION
• 9.4 HEALTHCARE SIMULATION SOFTWARE
  • 9.4.1 ABILITY TO REDUCE OVERALL SURGICAL PROCESS TRAINING TIME TO DRIVE ADOPTION
• 9.5 SIMULATION TRAINING SERVICES
  • 9.5.1 VENDOR-BASED TRAINING
    • 9.5.1.1 High focus on patient safety to drive demand
  • 9.5.2 EDUCATIONAL SOCIETIES
    • 9.5.2.1 Growing need for proper training and authenticity of knowledge to drive growth
  • 9.5.3 CUSTOM CONSULTING SERVICES
    • 9.5.3.1 Growing need to limit errors associated with traditional medical training systems to drive growth

10 MEDICAL SIMULATION MARKET, BY TECHNOLOGY

• 10.1 INTRODUCTION
• 10.2 VIRTUAL PATIENT SIMULATION
  • 10.2.1 INCREASING FOCUS ON AUGMENTED REALITY/VIRTUAL REALITY TO DRIVE MARKET
• 10.3 3D PRINTING
  • 10.3.1 INCREASING ADOPTION IN MEDICAL TRAINING TO DRIVE MARKET
• 10.4 PROCEDURAL REHEARSAL TECHNOLOGY
  • 10.4.1 NEED FOR ADVANCING SURGICAL SKILLS WITH REHEARSAL TECH TO FUEL MARKET GROWTH

11 MEDICAL SIMULATION MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 ACADEMIC INSTITUTES
  • 11.2.1 GROWING NEED FOR SKILLED MEDICAL PROFESSIONALS TO DRIVE DEMAND
• 11.3 HOSPITALS
  • 11.3.1 RISING FOCUS ON MINIMIZING MEDICAL ERRORS TO DRIVE DEMAND
• 11.4 MILITARY ORGANIZATIONS
  • 11.4.1 EXPLORATION OF NEW METHODS OF MEDICAL CARE DURING WARFARE TO DRIVE DEMAND
• 11.5 OTHER END USERS

12 MEDICAL SIMULATION MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 12.2.2 US
    • 12.2.2.1 Increasing demand for virtual tutors and high healthcare spending to boost growth
  • 12.2.3 CANADA
    • 12.2.3.1 Clinical simulation and competency-based training in Canada to fuel market growth
• 12.3 EUROPE
  • 12.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 12.3.2 GERMANY
    • 12.3.2.1 High healthcare spending to drive market growth
  • 12.3.3 FRANCE
    • 12.3.3.1 Growing focus on use of innovative methods in medical training to drive growth
  • 12.3.4 UK
    • 12.3.4.1 Rising number of healthcare simulation centers and hospitals to drive growth
  • 12.3.5 ITALY
    • 12.3.5.1 Shortage of trained healthcare personnel to drive growth
  • 12.3.6 SPAIN
    • 12.3.6.1 Increasing number of surgical procedures to boost growth
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 12.4.2 CHINA
    • 12.4.2.1 Increasing demand for trained medical professionals to drive growth
  • 12.4.3 JAPAN
    • 12.4.3.1 Increasing demand for virtual tutors and technologically advanced simulators to drive growth
  • 12.4.4 INDIA
    • 12.4.4.1 Growing awareness regarding patient safety due to healthcare negligence to drive growth
  • 12.4.5 AUSTRALIA
    • 12.4.5.1 Accreditation-driven training and national workforce policies to fuel medical simulation adoption in Australia
  • 12.4.6 SOUTH KOREA
    • 12.4.6.1 Technology-driven innovation and national digital health initiatives to accelerate adoption of medical simulation in South Korea
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 12.5.2 BRAZIL
    • 12.5.2.1 High incidence of chronic diseases to drive market
  • 12.5.3 MEXICO
    • 12.5.3.1 Disruptive technologies and public-private partnerships to boost growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Focus on enhancing patient care to drive market
    • 12.6.2.2 Saudi Arabia
      • 12.6.2.2.1 Government-led digital transformation and strong investments in AI-driven healthcare to boost market
    • 12.6.2.3 UAE
      • 12.6.2.3.1 Quality-driven healthcare strategy and institutional investments to accelerate simulation demand in UAE
    • 12.6.2.4 Rest of GCC Countries
  • 12.6.3 SOUTH AFRICA
    • 12.6.3.1 Evolving facility accreditation and workforce training needs to accelerate simulation adoption
  • 12.6.4 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2026
• 13.3 REVENUE ANALYSIS, 2021-2025
• 13.4 MARKET SHARE ANALYSIS, 2025
• 13.5 BRAND/PRODUCT COMPARISON
• 13.6 COMPANY VALUATION & FINANCIAL METRICS
  • 13.6.1 FINANCIAL METRICS
  • 13.6.2 COMPANY VALUATION
• 13.7 MARKET RANKING ANALYSIS, 2025
• 13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 13.8.1 STARS
  • 13.8.2 EMERGING LEADERS
  • 13.8.3 PERVASIVE PLAYERS
  • 13.8.4 PARTICIPANTS
  • 13.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 13.8.5.1 Company footprint
    • 13.8.5.2 Region footprint
    • 13.8.5.3 Product & service footprint
    • 13.8.5.4 Technology footprint
    • 13.8.5.5 End-user footprint
• 13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 13.9.1 PROGRESSIVE COMPANIES
  • 13.9.2 RESPONSIVE COMPANIES
  • 13.9.3 DYNAMIC COMPANIES
  • 13.9.4 STARTING BLOCKS
  • 13.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 13.9.5.1 Detailed list of key startups/SMEs
    • 13.9.5.2 Competitive benchmarking of key startups/SMEs
• 13.10 COMPETITIVE SCENARIO
  • 13.10.1 PRODUCT LAUNCHES & ENHANCEMENTS
  • 13.10.2 DEALS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 SURGICAL SCIENCE SWEDEN AB
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product enhancements
      • 14.1.1.3.2 Deals
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 LAERDAL MEDICAL
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches
      • 14.1.2.3.2 Deals
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 GAUMARD SCIENTIFIC
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches
      • 14.1.3.3.2 Deals
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Right to win
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 KYOTO KAGAKU CO., LTD.
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 MnM view
      • 14.1.4.3.1 Right to win
      • 14.1.4.3.2 Strategic choices
      • 14.1.4.3.3 Weaknesses & competitive threats
  • 14.1.5 LIMBS & THINGS LTD.
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches
      • 14.1.5.3.2 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Right to win
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses & competitive threats
  • 14.1.6 MENTICE AB
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches & approvals
      • 14.1.6.3.2 Deals
  • 14.1.7 SIMULAB CORPORATION
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product launches & enhancements
  • 14.1.8 SIMULAIDS
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
  • 14.1.9 OPERATIVE EXPERIENCE, INC.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Other developments
  • 14.1.10 ELEVATE HEALTHCARE
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
  • 14.1.11 ANATOMAGE
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Product launches & enhancements
      • 14.1.11.3.2 Other developments
  • 14.1.12 3B SCIENTIFIC
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
  • 14.1.13 VIRTAMED AG
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product enhancements
      • 14.1.13.3.2 Deals
  • 14.1.14 SYNBONE AG
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
  • 14.1.15 ERLER-ZIMMER MEDICAL GMBH
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
  • 14.1.16 MEDICAL-X
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products offered
  • 14.1.17 KAVO DENTAL
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products offered
  • 14.1.18 ALTAY SCIENTIFIC
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products offered
  • 14.1.19 TRUCORP LIMITED
    • 14.1.19.1 Business overview
    • 14.1.19.2 Products offered
    • 14.1.19.3 Recent developments
      • 14.1.19.3.1 Product launches
      • 14.1.19.3.2 Deals
  • 14.1.20 SIMENDO
    • 14.1.20.1 Business overview
    • 14.1.20.2 Products offered
• 14.2 OTHER PLAYERS
  • 14.2.1 HAAG-STREIT AG
  • 14.2.2 SONOSIM
  • 14.2.3 HRV SIMULATION
  • 14.2.4 SYNAPTIVE MEDICAL
  • 14.2.5 INOVUS LIMITED

15 RESEARCH METHODOLOGY

• 15.1 RESEARCH APPROACH
  • 15.1.1 SECONDARY RESEARCH
    • 15.1.1.1 Key data from secondary sources
  • 15.1.2 PRIMARY RESEARCH
    • 15.1.2.1 Primary sources
    • 15.1.2.2 Key data from primary sources
    • 15.1.2.3 Breakdown of primary interviews
    • 15.1.2.4 Insights from primary experts
• 15.2 RESEARCH METHODOLOGY DESIGN
• 15.3 MARKET SIZE ESTIMATION
• 15.4 DATA TRIANGULATION
• 15.5 RESEARCH ASSUMPTIONS
• 15.6 RESEARCH LIMITATIONS
  • 15.6.1 METHODOLOGY-RELATED
  • 15.6.2 SCOPE-RELATED
• 15.7 RISK ASSESSMENT

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS